DEPTH Trial (Emphysema in People Living with HIV)

Purpose of this Study

If you choose to join this study, you will complete up to 10 study visits and 2 phone call check-ins over 72 weeks. This study includes:<ul>
<li>Pulmonary function tests (how well your lungs are working)</li>
<li>CT scans of the chest (a special type of imaging that creates 3D X-ray images)</li>
<li>Blood draws</li>
<li>Questionnaires</li></ul>
During the study, you will be randomized (like flipping a coin) to get either:
<li>The study drug (Doxycycline) by mouth twice a day for 72 weeks; OR</li>
<li>A placebo (sugar pill) by mouth twice a day for 72 weeks</li></ul>

Who Can Participate?

Eligibility

Adults ages 30+ who:<ul>
<li>Are living with HIV</li>
<li>Have smoking-related lung disease</li></ul>
For more information about who can join this study, please contact the study team at depth-trial@duke.edu or 919-684-2285.

Age Range

30-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

We are doing this study to learn more about whether Doxycycline (an antibiotic medication) will help slow the progression of emphysema, or COPD.

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

Yes

Spanish Materials Available

No

Study Details

Full Title

Doxycycline for Emphysema in People Living with HIV (The DEPTH Trial)

Principal Investigator

David
Murdoch

Protocol Number

PRO00111021

NCT ID

NCT05382208

Phase

II

Enrollment Status

Open to Enrollment